Patients with acute myeloid leukemia (AML) in relapse or refractory to induction therapy have a dismal prognosis. Allogeneic hematopoietic stem cell transplantation is the only curative option. In these patients, we aimed to compare the results of a myeloablative transplant versus a sequential approach consisting in a cytoreductive chemotherapy followed by a reduced intensity conditioning regimen and prophylactic donor lymphocytes infusions. We retrospectively analyzed 99 patients aged 18-50 years, transplanted for a refractory (52%) or a relapsed AML not in remission (48%).
mortality was not higher in the myeloablative group (17% versus 15%, P 5 .44). In multivariate analysis, overall survival, CIR and nonrelapse mortality remained similar between the two groups.
However, in multivariate analysis, sequential conditioning led to fewer acute grade II-IV graft versus host disease (GVHD) (HR for sequential approach 5 0.37; 95% CI: 0.21-0.65; P < .001) without a significant impact on chronic GVHD (all grades and extensive). In young patients with refractory or relapsed AML, myeloablative transplant and sequential approach offer similar outcomes except for a lower incidence of acute GvHD after a sequential transplant.
| I N TR ODU C TI ON
Refractory or relapsed acute myeloid leukemia (AML) is associated with a dismal prognosis. Approximately, one third of patients younger than 60 years with newly diagnosed AML fail to achieve complete remission (CR) after induction therapy. 1, 2 For these resistant patients, chemotherapy alone does not offer any chance of cure. 3 Moreover, among complete responders to induction therapy, half of patients experiences relapse. 1, 2 The probability to obtain a second remission with salvage chemotherapy is lower and patient prognosis is poor 2 with a 5-year overall survival (OS) rate close to 5% to 20%. [4] [5] [6] [7] [8] To date, allogeneic hematopoietic stem cell transplantation (HSCT)
is the only potentially curative approach in patients with primary induction failure (PIF) or patients who relapsed, and failed to achieve a second remission. [5] [6] [7] [8] [9] [10] [11] In this setting, conventional myeloablative conditioning (MAC) transplants are usually associated with nonrelapse mortality (NRM) greater than 40% in historical series. [12] [13] [14] [15] [16] [17] More recently, promising results have been reported in patients with refractory or relapsed AML, using a sequential (SEQ) treatment approach.
This strategy consists in an initial cytoreductive chemotherapy followed by a reduced-intensity conditioning regimen transplant (RIC) to limit toxicity. Prophylactic donor lymphocyte infusions (DLI) are systematically planned, in the absence of graft versus host disease (GVHD) to reinforce the graft versus leukemia (GVL) effect. 18 Sequential approaches are associated to 30%-45% long-term survival in advanced AML patients. [19] [20] [21] [22] [23] Conversely, major advances in the supportive care of HSCT, such as fungal and viral infections prevention and treatment, or HLA-typing in unrelated transplants, have reduced NRM after MAC transplants. [24] [25] [26] [27] This evolution leads to reassess the role of MAC transplants in relapsed or refractory AML.
In the present study, we retrospectively analyzed data from the 
| Treatment
MAC consisted of 12 Gy-fractionated total body irradiation (TBI) or 12.8 mg/kg intravenous (IV) busulfan, both associated with cyclophosphamide. Sequential conditioning regimen was administered as previ- 
| Outcomes
The neutrophil recovery was defined as three consecutive days with a neutrophil count >0.5 3 10 6 /L. Platelet recovery was defined as three consecutive days with a platelet count above 50 3 10 9 /L at least 7 days after the last platelet transfusion. Acute GVHD (aGVHD) and chronic GVHD (cGVHD) were defined and staged as previously reported.
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| Statistics
Patient-, disease-and transplantation related characteristics were compared using the chi-square test for categorical variables, Kendall's tau for ordinal variables and the Student t test for continuous variables.
The Kaplan-Meier method was used to calculate the probability of OS (from the day of transplant to the day of death) and the probability of disease free survival (DFS) (relapse or death being considered as events 
| R E SU LTS
| Patients characteristics
Ninety-nine patients were included, 41 in the MAC and 58 in the SEQ groups. At transplant, 51 patients were in PIF. Two of these patients lacked hematopoietic recovery at 50 days post induction and 4 received only one intensive chemotherapy course before the transplant, including one who also received additional hypomethylating agent therapy courses. Forty-eight patients were in relapse with active disease. Characteristics are summarized in Table 1 . Median age at transplant was 40 in both groups. There was no difference between the 2 groups regarding the ELN classification, the number of lines of chemotherapy prior to HSCT and the status of disease at transplant.
There was a trend for a longer time between diagnosis and day of transplant in the sequential approach group (7.5 months vs 5 months, P 5 .055). Peripheral, but not bone marrow blast percentages at transplant were higher in the SEQ group (7 vs 1% (P 5 .01)).
| Transplant modalities
MAC regimen consisted of busulfan plus cyclophosphamide in 59% of patients and in TBI plus cyclophosphamide in 41% of patients. (Table 2 ).
There were no differences between the two approaches in terms 
| Risk factors for post-transplant outcomes in multivariate analysis
In multivariate analysis, sequential regimen remained associated with a Table 2 ).
In multivariate analysis including the conditioning regimen type, two variables were significantly associated with OS: relapse status (HR: (1.08-2.23); P 5 .017), and a higher blood blast percentage at transplant (HR: 1.01, 95%CI (1.01-1.02); P 5 .004) were independently associated with higher post-transplant CIR, while there was no significant prognostic factor for NRM in our cohort.
After excluding from the analyses the four patients, who had received only one induction therapy before transplant and the two patients lacking a hematopoietic recovery 50 days after induction therapy, the conditioning regimen remained not statistically associated with OS, DFS, NRM, CIR, cGVHD but is still significantly associated with aGVHD (Supporting Information Table S1 ).
| Subgroup analysis
To identify a subgroup of patients who may benefit from the SEQ or the MAC approaches, we analyzed the impact of the conditioning regimen according to the presence of blood blasts at transplant and to the Our results showing a 2-year OS of about 40% compared favorably with previous series of MAC and sequential HSCT in relapsing or refractory AML. 9, 10, 12, 15, [19] [20] [21] 23, [32] [33] [34] [35] Patients from two groups did not differ in regards to their major characteristics, especially the distribution between refractory and relapsed leukemia. Types of donor and stem cell sources were not significantly different between the 2 groups, but most patients in the SEQ group received ATG in their conditioning regimen, unlike patients of the MAC group (84% versus 10%, P < .001).
We observed very close OS, DFS, relapse and NRM after a SEQ or a MAC transplant, and we failed to identify a subset of patients benefiting from one of these approaches rather than the other. The 2-year NRM of 17% we observed in the MAC group, was lower than reported in the historical series, 12, 13, 17 reflecting the progress in supportive care during the last decades. 25, 27 We confirm here that refractory status is associated with a better OS than relapse status, as previously reported in the setting of sequential transplant. 19 Furthermore, Holtick et al recently showed that PIF and high-risk AML transplanted in first CR display identical OS and DFS after FLAMSA regimen, suggesting that patients in PIF seem to really benefit from early stem cell transplantation. 22 The main difference between the 2 approaches was a lower incidence of grade II-IV aGVHD observed in the SEQ group. This difference remained significant in multivariate analysis including ATG, but did not translate into lower cGVHD. Interestingly, RIC regimen seems to be less toxic to gonads. In our experience, two spontaneous pregnancies were observed a few years after SEQ transplant in two young females (N. Dhedin et al., unpublished data).
One limit of this retrospective study is to ignore the reason why physicians choose a SEQ approach or a MAC conditioning regimen.
Moreover, each group of treatment featured different types of conditioning regimen: TBI or busulfan based regimen in the MAC group and clofarabine plus aracytine versus FLAMSA regimens in the SEQ group.
Finally, the main difference was a more frequent use of ATG in the SEQ group, which had a major impact on chronic GVHD occurrence, as previously reported. [36] [37] [38] In high-risk AML, relapse after transplant remains the major cause of death, leading to the recommendation of prophylactic DLI in the sequential approach. In several series of SEQ transplants, the addition of prophylactic DLI was associated with prolonged OS achieving 67% at 7 years in a large report from the German group. 19, [39] [40] [41] In our retrospective study, only 8.6% of patients transplanted after a SEQ approach actually received prophylactic DLI. That is lower than previously reported in the experience of the German group. [18] [19] [20] However, in most studies of SEQ transplant, prophylactic DLI did not exceed 25%, [18] [19] [20] 23, 34 due to early transplant mortality, early relapse or GVHD occurrence, actually showing the poor feasibility of this strategy.
Another way of reducing post-transplant relapse in SEQ approach could be to reinforce the pretransplant cytoreduction by using news drugs. A second generation of purine analog, clofarabine, which also shown to be relevant in first line or in relapsed of AML, [42] [43] [44] was thus evaluated in the setting of sequential transplant. 21, 35 In our series there is no superiority of a clofarabine/cytarabine-RIC compared with a more classic FLAMSA-RIC regimen. These data are consistent with the results of the prospective SETRIC trial reporting a 2-year OS of 38%
after a clofarabine/cytarabine-RIC in refractory AML patients. 21 Finally, new strategies of maintenance therapies are being developed, alone or in combination with prophylactic DLI to avoid post-transplant relapse.
The hypomethylating agent azacitidine or the tyrosine kinase inhibitor sorafenib for FLT3-ITD patients have shown tolerability and feasibility as maintenance therapies after transplant and seem to improve OS and DFS rates. 45, 46 Such therapies, including also new tyrosine kinase inhibitors that can target a broader spectrum of patients, have to be evaluated in these patients, especially in those at a very high risk of relapse, such as patients with persisting blood blasts.
In conclusion, our study shows that, for young patients with refractory or relapsed AML, OS, DFS, NRM and CIR appear to be similar after sequential and myeloablative transplants. Lower acute GVHD incidence in the sequential group did not lead to lower cGVHD. Post-transplant relapse remains a major issue and maintenance therapy after transplant is a promising possibility, which has to be prospectively evaluated.
